Myrtelle, Inc. is a clinical-stage biotechnology company headquartered in Wakefield, Massachusetts, developing gene therapies for myelin-based disorders of the central nervous system. Its lead program, MYR-101 (rAAV-Olig001-ASPA), is a first-in-class oligotrophic recombinant adeno-associated virus gene therapy for Canavan disease, a rare and fatal childhood genetic brain disease caused by mutations in the ASPA gene. The program is licensed exclusively worldwide from Pfizer Inc., holds Orphan Drug, Fast Track and Rare Pediatric Disease designations in the US with similar designations in Europe, and has reported Phase 1/2 interim results in Nature Medicine. Myrtelle is a therapeutics developer, not a software company: it publishes no developer program, API, SDK or machine-readable API contract, and is profiled here for network completeness only.
Myrtelle is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Gene Therapy, Life Sciences, and Pharmaceuticals.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/myrtelle: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: myrtelle
name: Myrtelle
description: 'Myrtelle, Inc. is a clinical-stage biotechnology company headquartered in Wakefield, Massachusetts, developing
gene therapies for myelin-based disorders of the central nervous system. Its lead program, MYR-101 (rAAV-Olig001-ASPA),
is a first-in-class oligotrophic recombinant adeno-associated virus gene therapy for Canavan disease, a rare and fatal childhood
genetic brain disease caused by mutations in the ASPA gene. The program is licensed exclusively worldwide from Pfizer Inc.,
holds Orphan Drug, Fast Track and Rare Pediatric Disease designations in the US with similar designations in Europe, and
has reported Phase 1/2 interim results in Nature Medicine. Myrtelle is a therapeutics developer, not a software company:
it publishes no developer program, API, SDK or machine-readable API contract, and is profiled here for network completeness
only.'
url: https://raw.githubusercontent.com/api-evangelist/myrtelle/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Gene Therapy
- Life Sciences
- Pharmaceuticals
- Clinical Trials
- Rare Disease
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/myrtelle-domain-security.yml
- type: Website
url: https://myrtellegtx.com/
x-enrichment:
date: '2026-08-26'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Myrtelle is a clinical-stage gene therapy developer (lead program MYR-101 / rAAV-Olig001-ASPA for Canavan disease)
with no developer program of any kind — its reachable property canavantreatment.com 404s on every OpenAPI, GraphQL, llms.txt,
agent-card and /.well-known/ path and exposes only stock WordPress core routes at /wp-json, no GitHub organization exists
(api.github.com/orgs/myrtelle returns 404), and no first-party package is published to npm or PyPI.
evidence:
- url: https://canavantreatment.com/openapi.json
status: 404
- url: https://canavantreatment.com/.well-known/agent-card.json
status: 404
- url: https://canavantreatment.com/llms.txt
status: 404
- url: https://api.github.com/orgs/myrtelle
status: 404
- url: https://pypi.org/pypi/myrtelle/json
status: 404
checked: '2026-08-26'
Kin Score
How this is scored →